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   EDITORIAL
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Dear colleagues,
The past 20 years have been witness to remarkable progress 
with respect to the treatment of pulmonary diseases. 
However, troubling realities exist despite better outcomes. 
The focus of this supplement is to review new treatment 
modalities in pulmonary medicine.
It has long been known that asthma usually has an early 
onset with intermittent symptoms, has a good response to 
inhaled therapy, and is often associated with other allergic 
diseases, whereas chronic obstructive pulmonary disease 
(COPD) is of late onset, has progressive symptoms, a poor 
response to inhaled therapy, and is usually associated with 
smoking. However, real life data have shown that some 
patients can  occasionally have features of both diseases, and 
this condition has been termed the asthma-COPD overlap 
syndrome (ACOS). This new terminology is discussed by 
Dr.Kocakaya in this issue  [1].
There is an executive summary written by Dr. Peker. 
This is entitled “Obstructive Sleep Apnea and Driving Risk: 
The current Turkish legislation, controversies and future 
perspectives”. This article updates recommendations based 
on the current literature in this field  [2].
Several novel and potentially less invasive methods for 
bronchoscopic lung volume reduction have been developed 
over past years for patients with advanced emphysema. The 
choice of endobronchial therapy largely depends on the 
distribution of the emphysema and the presence or absence 
of interlobar collateral ventilation. Dr. Olgun Yildizeli 
highligts the information about endobronchial coil and valve 
implementation in COPD patients [3]. 
New treatment approaches are evolving in the treatment of 
severe asthmatics. The efficacy of bronchial thermoplasty is 
promising for patients whose asthma  symptoms are not 
controlled despite medical therapy. Dr. Sagmen  reviews the 
literature about bronchial thermoplasty and reports which 
patient will respond to bronchial thermoplasty [4].
COPD guidelines recommend the combined use of 
inhaled long-acting β2-agonists (LABAs) and long-acting 
muscarinic antagonists (LAMAs) if symptoms are not 
improved by a single agent. Dr. Balcan has written about the 
latest developments in bronchodilator treatment in COPD 
patients [5].
People with asthma and COPD are considered to be 
at risk for complications of influenza. This virus has been 
responsible for a major increase in morbidity and mortality 
during epidemic periods, especially in such patients. Each 
year, an average of 20,000 people die of influenza-related 
illness in the United States  [6]. Vaccination remains the 
primary preventive strategy. Annual influenza vaccination 
in COPD decreased the rates of hospitalization, pneumonia, 
and deaths among the elderly and people with high-risk 
conditions. The other major impact on population health is 
pneumonia. The Centers for Disease Control and Prevention 
recommend pneumococcal vaccination for all patients ≥ 
65 year of age as well as for younger patients with chronic 
medical illnesses, including COPD.  I summarize  recent 
recommendations about influenza and pneumococcal 
vaccine [7].
Improved survival rate in patients with acute respiratory 
failure requiring mechanical ventilation have recently 
resulted from the developments in respiratory intensive care 
units. New data are emerging daily from intensive care units. 
In addition to the current information about noninvasive 
mechanical ventilation, new modalities in intensive care 
units such as ultrasonography,  ECMO, hypothermia are 
reviewed by Dr.Karakurt et al. [8,9]. 
I would especially thank to all of the authors in this issue 
for writing these manuscripts. Also, I thank to Dr. Pamir 
Atagunduz for his positive approach to accomplishing a 
special issue on Pulmonary Medicine.
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